Introduction: Insomnia is the most commonly reported sleep disorder and remains undertreated in many patients. New changes to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, have changed the way insomnia is diagnosed. In patients who suffer from insomnia, a number of available treatment options exist including both behavioral therapy and medications. Literature Review: First line therapy for insomnia should always include behavioral modifications such as sleep hygiene and insomnia-oriented cognitive behavioral therapy. In patients deemed to need pharmacotherapy, first line medications include nonbenzodiazepine hypnotics (i.e., z-drugs) and antidepressants depending on the patients' needs and comorbidities. The risk of next day impairment, parasomnias, and central nervous system depression are some of the most feared side effects with z-drugs. Second line drug therapy includes melatonin and suvorexant. Several concerns exist for suvorexant similar to other insomnia medications, but melatonin remains one of the safest medication alternatives. Other medication options such as benzodiazepines, antihistamines, and antipsychotics should rarely be used because of weak effectiveness data or serious safety concerns. Discussion: The most appropriate treatment plan needs to be tailored to meet the needs of individual patients. Many patient factors (e.g., age, other comorbidities, specific problems with sleep) need to be considered before prescribing drug therapy
Introduction
Insomnia is the most common sleep disorder with nearly one third of people in the United States experiencing symptoms and approximately 6% of people meeting criteria for a sleep disorder. 1 Insomnia is characterized by difficulty initiating sleep, frequent awakenings, or the inability to return to sleep, and it becomes a disorder once a patient has daytime impairment. 2 Insomnia is often underrecognized and undertreated. Even when it is recognized, comorbid insomnia may not be treated because other medical or psychiatric conditions often take priority. 3 A number of treatment modalities have been developed to treat insomnia including cognitive behavioral therapy, sleep environment modifications, and medications. 4 The intent of this article is to review the changes in diagnosing insomnia from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5) as compared to previous DSM-IV criteria as well as discuss nonpharmacologic and pharmacologic management strategies to effectively treat insomnia. 2 
Literature review

Diagnostic criteria changes
Several changes were made with the most recent DSM-5 criteria for sleep-wake disorders to better classify medical disorders and sleep disorders. A summary of these changes can be seen in Table 1 . The main changes include new criteria for the frequency and duration of symptoms needed to diagnose insomnia, identification of other subtypes of sleep disorders, and the elimination of primary and secondary classification to characterize a patient's insomnia and other medical disorders. 2 
Nonpharmacologic treatment
Sleep hygiene is an important first step in the treatment of insomnia. Appropriate interventions include creating an environment conducive to sleep, avoiding going to bed until drowsy, getting out of bed in 15-20 minutes if not asleep, setting a regular sleep schedule, and avoiding daytime napping. 4 In addition, discussing with patients the importance of avoiding caffeine, nicotine, alcohol, and stimulants within 6 hours of bed remains an important counseling point. When educating patients about exercise, clinicians should encourage regular exercise but avoid exercising within 4 hours of attempting to fall asleep. Finally, avoiding activities such as reading or watching television in bed should be emphasized to develop an association for bed as the place for sleep.
Along with sleep hygiene, cognitive behavioral therapy (e.g., replacing dysfunctional beliefs, relaxation) should be considered first line because it is effective at improving long-term insomnia and has few risks. 5 Insomnia is a common 6 In fact, there is some evidence that CBT-I is more effective than medications for long-term benefit for insomnia. CBT-I involves patients keeping a thought diary to record troubling thoughts and concerns plus sleep restriction and stimulus control. This can be coupled with relaxation therapy through yoga, meditation, and progressive muscle relaxation. 7 Mobile applications, such as CBT-I coach through the Veterans Affairs, provide a novel and accessible supplement to CBT-I for patients. CBT-I coach is a central place to track sleep habits, provide tools (e.g., relaxation breathing, guided imagery), and encourage positive reinforcement. 8 As insomnia is multifactorial, appropriate management of comorbid medical illness should be emphasized. In particular, obstructive sleep apnea, pain disorders, mood disorders, substance use disorders, and nocturia should all be treated effectively. For a summary of nonpharmacologic strategies for managing insomnia, see Table 2 .
Pharmacologic treatment
Choosing medications to augment nonpharmacologic management of insomnia is challenging because of the number of possible drugs for insomnia, side effects seen from these therapies, and a lack of long-term trials indicating the safest and most effective medicine. For an overview of common medications used in insomnia, see Table 3 . This chart lists the most common medications used per class of hypnotic, common doses, pharmacokinetic properties, role in therapy, and therapeutic concerns.
Nonbenzodiazepine hypnotics or z-drugs are likely the class of drug most clinicians use first line for patients with insomnia because they are the best studied, modestly effective, and possess fewer concerns than other options such as benzodiazepines. Each medication in this class will reduce sleep latency by approximately 20 minutes, but the effects on total sleep time vary. 9 When choosing between these drugs, immediate release zolpidem is likely the best option for helping patients reduce sleep latency and increase total sleep time. It is important to note that United States Food and Drug Administration (FDA) established dosing limits in 2014 for zolpidem reducing the maximum dose in women to 5 mg of the immediate release product and 6.25 mg of the extended release drug. This warning stemmed from literature indicating women are less able to metabolize zolpidem making their drug levels higher than men taking the same dose. Zolpidem extended release offers no added benefit considering there is sparse evidence of safety and effectiveness of zolpidem extended release, and an extended delivery system may cause higher rates of side effects such as next day impairment due to its longer action. 10 Zaleplon is an alternative to zolpidem for patients trying to fall asleep or those who have periodic nighttime awakening and want to take a medication midway through the night. Its short half-life makes it less helpful for sleep maintenance, but theoretically it possess less risk for causing next day impairment. 11 Eszopiclone should be avoided because its longer half-life potentially increases the risk of next day impairment, and up to one third of patients may report the unique side effect dysgeusia, making other z-drugs better options. Overall, there are numerous concerns with the safety of z-drugs. Patients should be cautioned about parasomnias (e.g., sleep eating, sleepwalking, nightmares, confusional arousals) and the risk of next day impairment when starting treatment among other cautions. 10 There is also concern that long-term use of z-drugs may increase the risk of cardiovascular events, cancer, and all-cause mortality, but the data thus far have only come from observational trials and findings have been inconsistent. [12] [13] [14] Antidepressants are a strong treatment alternative especially in patients reporting comorbid mood disorders. Cognitive behavioral therapy as noted above is a more effective long-term solution for insomnia than simply using an antidepressant. 7 That said many patients will not obtain complete remission of their symptoms of depression with nonpharmacologic therapy alone so may benefit from a trial of an antidepressant. Similar to prescribing with other mood disorders antidepressants should be primarily chosen based on side effects and preference should be given to antidepressants with more evidence of benefit in insomnia.
Low-dose doxepin at 3 mg and 6 mg at bedtime is the antidepressant with the most proven benefits because data support that it reduces sleep latency and increases total sleep time without impairing sleep quality. 10 Unfortunately, these doses are only available in the brand product Silenor and the lowest dose for the cheaper generic immediate release option is a 10 mg capsule. Mirtazepine is another commonly used antidepressant in patients with comorbid insomnia and depression especially in older adults in need of gaining weight. At lower doses (i.e., 7.5-15 mg), mirtazepine has more sedating properties, whereas the higher doses might be more helpful for improving depression. 15 Most other classes of antidepressant such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants all can be considered as treatment for insomnia in patients with significant mood disorders but should be monitored closely and avoided with serious precautions. 16 Benzodiazepines remain a popular class of medications prescribed for patients with insomnia. These agents will increase total sleep time and reduce sleep latency, but they may impair sleep quality and increase the risk of physical dependence. 17 Similar concerns for next day impairment, parasomnias, and central nervous system (CNS) depression exist like the z-drugs. They also have additional concerns of anterograde amnesia, falls, drug-drug interactions, respiratory depression, withdrawal, dependence, and substance abuse. 4, 10 As a result, benzodiazepines should be used as a last line alternative in patients who have failed all other therapies and require short-term intermittent treatment with a medication.
A new class of hypnotic was introduced in 2014 when the FDA approved suvorexant an orexin receptor antagonist. Unlike many medications that promote sedation via increased gabaminergic effects, it antagonizes orexin a wakefulness promoting hormone. When taken at bedtime similar to z-drugs, suvorexant produces similar benefits on decreasing sleep latency and increasing total sleep time without causing impairment in sleep quality. 10 Similar adverse effects are seen with suvorexant as with other hypnotics as reported in Table 3 .
Suvorexant has unique concerns with use including drug-drug interactions (e.g., strong CYP 3A4 inhibitors and inducers), moderate concern for addiction, and a contraindication in patients' with narcolepsy. 10, 17 The narcolepsy contraindication is to prevent suvorexant from exacerbating this condition which is thought to be caused at least in part by deficient orexin production throughout the day.
Melatonin agonists (e.g., controlled release melatonin, ramelteon) remain a safe treatment alternative with few side effects, but data showing its benefit for insomnia are weaker than other drug classes. Evidence for melatonin has shown an approximately 7-minutes reduction in sleep latency, an 8-min increase in total sleep, and improvements in sleep quality when compared to placebo. 18 These treatments likely have more benefit for circadian rhythm disorders (e.g., jet lag, shift work) or in delirium prevention. Potency concerns and contamination with other sleep medications such as antihistamines and benzodiazepines exist for over the counter melatonin because the FDA does not regulate these products, and independent testing has identified purity concerns in many products. 17 Ramelteon has more robust safety and effectiveness data than melatonin, but its widespread use is limited since it is still an expensive prescription drug.
Several medication classes should be used with caution or avoided completely because safer alternatives exist. Antihistamines as a class should be avoided because data on long-term safety and efficacy are lacking. The phenomenon of tachyphylaxis may occur with chronic use. Moreover, there is concern that antihistamines can increase the risk of CNS depression and possibly impair sleep quality. 10, 17 Antipsychotics while often used for patients with insomnia should be reserved for patients with comorbid psychosis or significant mood disorders, like bipolar disorder, because of the extensive long-term risks. 17 Obtaining a full psychiatric history may help to best identify these patients because accurately diagnosing psychiatric illness remains difficult. 19 Finally, trazodone is one of the most popular medications for insomnia, but similar to antihistamines, patients may develop tachyphylaxis with daily low doses (e.g., 25-50 mg). When used at higher doses, it may have more benefit at improving depression, which in turn may reduce insomnia, but it is associated with many more risks than other antidepressants such as orthostatic hypotension and priapism in men. 10 Therefore, trazodone should be avoided because safer and more effective medications exist.
Case study
Each patient should be assessed on a case-by-case basis to see what the most reasonable treatment is and if patients are in need of nonpharmacologic therapy, medications, or a combination of the two. As an example of tailoring recommendations to a specific patient, we have included the experience of one of our patients treated for insomnia. We had an 82-year-old female with the medical history of osteoarthritis, hypertension, and type 2 diabetes who was seen in an outpatient clinic, several months after moving in with her daughter from living independently. The patient and her daughter expressed concern that the patient was having difficulty falling asleep 4-5 times per week and having early morning awakenings weekly. She noted more frequent daytime fatigue, increased irritability by her family, decreased appetite, and diminished interest in going to church despite previously being an active member. A clinical diagnosis of insomnia was made based on classic symptoms of insomnia associated with daytime impairment. A Patient Health Questionnaire-9 (PHQ-9) was also administered, 20 and she scored 14 of 27 points indicating she had comorbid moderate depression.
The physician and patient agreed to initiate mirtazapine 7.5 mg nightly to help improve symptoms of insomnia, depression, and low appetite. She also was counseled on maintaining a consistent sleep schedule, avoiding television in the bedroom, and getting out of bed and reading if unable to fall asleep within 20 min. In addition, our patient had an anxiety component to her depression so we recommended trying progressive muscle relaxation and the 4-7-8 breathing technique. On return visit two months later, she reported improved sleep quality, about half as many nights with having difficulty falling asleep, no early morning awakenings, and demonstrated an appropriate 11-pound weight gain. Her PHQ-9 score decreased to a 7 out of 27 indicating she then had mild symptoms of depression. She and her daughter reported they were very pleased with her progress.
Conclusions
Insomnia is a frequent complaint encountered by clinicians, and the myriad of treatment options to choose from can be overwhelming. Special consideration to individual patient comorbidities and needs should be weighed on a case-bycase basis.
Emphasis should be placed on improving sleep hygiene parameters after going through a sleep history with a patient and then considering other behavioral modifications such as CBT-I. Patients who fail nonpharmacologic interventions may benefit from first line medications such as zolpidem, zaleplon, and doxepin in combination with behavioral modifications. Benzodiazepines should be avoided, as there are safer alternatives with less abuse potential. Suvorexant has demonstrated improved short-term outcomes but has no clear benefits over z-drugs and is more expensive. 21 Finally, melatonin carries the least amount of side effects and is the safest pharmacologic approach, but it may be less effective than other drug treatment options for insomnia.
